



October 9, 2019

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Kind Attention: Mr. Piyush Tanna, Chief Manager, Surveillance.

Dear Sir,

Re: Clarification/Confirmation on news item appearing in "Media/Publication".

We refer to your letter Ref. No. NSE/CM/Surveillance/8658 dated October 7, 2019 (copy enclosed), seeking clarification on news item which appeared in the "economictimes.indiatimes.com" dated October 7, 2019, captioned "USFDA red flags Lupin for significant violations at MP unit".

We wish to state that the Company has promptly intimated your Exchange as regards Warning Letter and OAs. The source of the captioned article is our intimation to your Exchange relating to Mandideep facility Warning Letter.

The Warning Letter was issued in respect of the inspection carried out in December 2018, which in March 2019 was classified as OAI. The Warning Letter was specific to Mandideep facility only.

Trust we have clarified the matter.

Thanking you,

For **LUPIN LIMITED**

For 
R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)



Encl: - a/a.



National Stock Exchange Of India Limited

Ref. No.: NSE/CM/Surveillance/8658

Date: October 07, 2019

The Company Secretary,
Lupin Limited.

Dear Madam/Sir,

Sub: Clarification /Confirmation on news item appearing in "Media/Publication"

As per regulation 30 of the SEBI (LODR) Regulations, 2015, all listed companies are required to intimate to the Exchanges all the events, information etc. that have bearing on the operation/ performance of the company which include all price sensitive information, etc.

In addition, all listed companies are also required to provide specific and adequate reply to all queries raised by stock exchange(s) with respect to any events or information. The listed company may on its own initiative also, confirm or deny any reported event or information to stock exchange(s) which may have a bearing on the price / volume behavior in the scrip.

This is with reference to recent news item which appeared in the "economictimes.indiatimes.com" dated October 07, 2019 captioned "USFDA red flags Lupin for significant violations at MP unit"

In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following as applicable:

- a) Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.
- b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.
- c) The material impact of this article on the Company.

In case you/company are denying or are unaware of the abovementioned news item and its source, you are advised to state categorically that the abovementioned news item is factually incorrect.

You are therefore advised to provide clarification/confirmation in respect of the above news item to the Exchange before 09-Oct-2019 11:00 AM through **NEAPS > Reports > News Clarification > All** only.

Thanking you
Your's faithfully,

For National Stock Exchange of India Ltd.

Piyush Tanna
Chief Manager
Surveillance.

This document is electronically generated and does not require digital signature